Matarin Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-28,453	Closed	-$1.3M	–	198
2020 Q3	$1.3M	Buy	28,453 +16,270	+134%	+$788K	0.27%	135
2020 Q2	$612K	Buy	+12,183	New	+$630K	0.12%	169
2020 Q1	–	Sell	-136,217	Closed	-$8.41M	–	217
2019 Q4	$8.41M	Sell	136,217 -64,554	-32%	-$4M	0.8%	35
2019 Q3	$12.1M	Sell	200,771 -10,507	-5%	-$780K	0.91%	30
2019 Q2	$17.8M	Buy	211,278 +1,875	+0.9%	+$169K	1.27%	4
2019 Q1	$20M	Sell	209,403 -462	-0.2%	-$41.4K	1.46%	1
2018 Q4	$14.9M	Sell	209,865 -343	-0.2%	-$26.3K	1.2%	8
2018 Q3	$18M	Buy	210,208 +8,505	+4%	+$852K	1.16%	12
2018 Q2	$23.4M	Sell	201,703 -21,804	-10%	-$2.18M	1.69%	1
2018 Q1	$18.1M	Sell	223,507 -63,450	-22%	-$4.88M	1.36%	5
2017 Q4	$16.8M	Sell	286,957 -3,664	-1%	-$183K	1.31%	3
2017 Q3	$13.6M	Buy	290,621 +15,728	+6%	+$632K	1.16%	6
2017 Q2	$9.89M	Sell	274,893 -71,083	-21%	-$2.27M	0.92%	21
2017 Q1	$10.7M	Buy	345,976 +88,708	+34%	+$2.76M	1.05%	14
2016 Q4	$8.62M	Buy	257,268 +10,420	+4%	+$299K	0.97%	17
2016 Q3	$6.57M	Buy	246,848 +10,158	+4%	+$236K	0.72%	44
2016 Q2	$5.22M	Buy	236,690 +17,654	+8%	+$462K	0.71%	53
2016 Q1	$6.43M	Buy	219,036 +78,407	+56%	+$2.18M	0.9%	24
2015 Q4	$4.64M	Buy	140,629 +93,274	+197%	+$3.04M	0.69%	54
2015 Q3	$1.71M	Buy	+47,355	New	+$2.03M	0.35%	97